Acurx signals ongoing cost controls and new trial funding avenues while advancing ibezapolstat clinical program
Source: SeekingAlpha
2025-08-12 10:14:26 ET
More on Acurx Pharmaceuticals
- Acurx Pharmaceuticals, Inc. (ACXP) Q2 2025 Earnings Call Transcript
- Acurx Pharmaceuticals files $50M mixed shelf offering
- Seeking Alpha’s Quant Rating on Acurx Pharmaceuticals
- Historical earnings data for Acurx Pharmaceuticals
- Financial information for Acurx Pharmaceuticals
Read the full article on Seeking Alpha
For further details see:
Acurx signals ongoing cost controls and new trial funding avenues while advancing ibezapolstat clinical program
Acurx Pharmaceuticals Inc.
NASDAQ: ACXP
ACXP Trading
60.34% G/L:
$2.83 Last:
23,503,038 Volume:
$2.09 Open:
ACXP Latest News
March 09, 2026 08:01:00 am
Acurx Announces New Ibezapolstat Clinical Trial Program in Patients with Recurrent CDI That Has the Potential to Shift the Paradigm of Treatment and Prevention of C. difficile Infection
February 16, 2026 08:01:00 am
Acurx Pharmaceuticals to Discuss Full Year and Fourth Quarter 2025 Financial Results on March 13, 2026 Conference Call and Provide Business Update
February 02, 2026 08:00:00 am
USPTO Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors
ACXP Stock Data
$5,246,237
2,029,733
5.06%
9
N/A
Biotechnology & Life Sciences
Healthcare
US
Staten Island
